Navigating payer challenges in rare disease
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
For more than 25 years, life science companies, law firms, and regulatory agencies around the globe have turned to CRA’s life sciences consultants when they need clarity and solutions to the industry’s most complex issues. Clients value our deep industry knowledge, rigorous analytic techniques, and decades of hands-on experience spanning thousands of successful engagements.
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences...
Access to medicine and healthcare services poses persistent challenges, especially in low-income regions with high out-of-pocket expenses. Pharmaceutical...
Kirsten Axelsen moderates the PhRMA-sponsored panel session titled “Progress or Regress…How does CMS’ Maximum Fair Price Negotiation align with...
CRA is a proud sponsor of the MAPS organization. Ayushman Ghosh and Michelle Guo host the roundtable discussion titled “Strategic applications of Machine...
HBA New York Tri-State presents an engaging evening continuing the discussion of the intersection of Health Equity & Women’s Global Health. How chronic pain...
CRA is exhibiting at the conference at booth #2018. Matt Majewski presents his session titled “What is a Fair Price for a Rare Disease Therapy?”...